Drug utilisation evaluation of antiplatelet agents in a tertiary care teaching hospital-a prospective observational  study

Rishitha Reddy P; Prathul P; Jayalakshmi A; Anusha SB; Randeep Raj V.C

doi:10.47957/ijpda.v9i3.485

Authors

P.Rishitha Reddy Pharm.D Intern, Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Chittivalasa, Bhogapuram, Vizianagaram-531162, Andhra Pradesh, India
P.Prathul Pharm.D Intern, Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Chittivalasa, Bhogapuram, Vizianagaram-531162, Andhra Pradesh, India
A.Jayalakshmi Pharm.D Intern, Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Chittivalasa, Bhogapuram, Vizianagaram-531162, Andhra Pradesh, India
SB.Anusha Pharm.D Intern, Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Chittivalasa, Bhogapuram, Vizianagaram-531162, Andhra Pradesh, India
V.C.Randeep Raj Assistant professor,Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Cherukupally, Chittivalasa, Bhogapuram, Vizianagaram-531162, Andhra Pradesh, India

DOI:

https://doi.org/10.47957/ijpda.v9i3.485

Keywords:

Antiplatelet agents, aspirin, clopidogrel, dual antiplatelet therapy [DAPT], monotherapy, utilisation pattern and adverse event

Abstract

Background: Cardiovascular and cerebrovascular diseases were becoming predominant cause of morbidity and mortality in India. Antiplatelet agents remain as the cornerstone therapy for acute thrombotic coronary syndromes, IHD, STROKE, CHD and PCI and are essential for thromboprophylaxis. The current study was undertaken to evaluate the drug use pattern of antiplateletagents and to study the prescribing pattern, observe co-morbid conditions, social habits [alcohol/smoking], adverse events and drug-drug interactions associated with antiplatelet agents.

Methods: A prospective observational study was conducted at MIMS hospital, study population of 160 inpatients from cardiology, general-medicine and neurology departments. Data was analyzed in Microsoft excel.

Results: Data records obtained from 160 patients in which 51.87% were females followed by males 48.125%. most patients with IHD and stroke were found in age group 50-70 years. Hypertension was most found co-morbidity among the patients [61.88%] followed by diabetes [34.38%], hypothyroidism [5%], epilepsy[3.75%]. Utilisation pattern of antiplatelet agents aspirin, clopidogrel were found to be[97.5%] [82.5%] respectively. patients on DAPT[81%] were highest compared to monotherapy [19%]. Patients found with social habits were 38.75% smokers, 31.25% alcoholics and 22% both alcohol and smoking.

Conclusion: The present study concludes that DAPT [aspirin+clopidogrel] was found to be superior to monotherapy, and incidence of IHD which is more common in males compared to females. Patients in the group 51-70 were most affected with stroke, IHD and with female predominance over male. Antiplatelet therapy which is clearly efficacious in reducing the incidence of ischemic events/ thromboembolic events DAPT[aspirin+ clopidogrel] was most effective and reduced ischemic events, yet have the risk of bleeding or resistance. Newer anti platelet agents such a Prasugrel and Ticagrelor can be utilised considering the bleeding risk.

Downloads

Download data is not yet available.

References

P. Doherty, S. Kirsa, S. Chao et al., “SHPA standards of practice for drug use evaluation in australian hospitals: shpa committee of specialty practice in drug use evaluation,” Journal of Pharmacy Practice and Research, vol. 43, no. 3, pp. 220–223, 2004.

Management Sciences for Health and World Health Organization. 2007. Drug and Therapeutics Committee Training Course. Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Arlington, VA: Management Sciences for Health. https://www.who.int/.../tbs/11-PG_Drug-Use-Evaluation_final-08.pdf

Shaw PM, Gayman JE, Todd MW. ASHP Guidelines on medication-use evaluation. Health Syst Phann 1996; 53: 1953-5.

The Society of Hospital Pharmacists of Australia. Australian Drug Usage Evaluation Starter Kit, 1998.

Brown JC, Gerhardt TE, Kwon E. Risk Factors For Coronary Artery Disease. 2020 Jun 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32119297.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651. doi: 10.1136/openhrt-2017-000651.

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19. doi: 10.1056/NEJMoa1215340.

Dr. C. k. Wong, et, al. The Role of Antiplatelet Agents, BPJ, issue 19.

Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011 Feb;112(2):292-318. doi:10.1213/ANE.0b013e318203f38d. Epub 2011 Jan 6. PMID: 21212258.

Berry, C. (2017). Stable Coronary Syndromes: The Case for Consolidating the Nomenclature of Stable Ischemic Heart Disease. Circulation, 136(5), 437–439. https://doi.org/10.1161/circulationaha.117.028991.

Pramodh, B., Kumar, M. A., & Shanmugasundaram, P. (2017). A Prospective Observational Study on Drug use Evaluation of Antiplatelet Agents in Tertiary Care Hospital. Research Journal of Pharmacy and Technology, 10(12), 4328. https://doi.org/10.5958/0974-360x.2017.00793.4.

K. Jyothi, et, al. A Retrospective Drug Utilization Study of Antiplatelet Drugs in Patients with Ischemic Heart Disease.[International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering Vol:9, No:7, 2015].

Angiolillo DJ. Anti-platelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32:531–540.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P,Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-5.

Reddy, T. & Prasad T S, Durga & Swetha, S. & Nirmala, G. & Ram, P.. (2018). A study on antiplatelets and anticoagulants utilisation in a tertiary care hospital. International Journal of Pharmaceutical and Clinical Research. 10. 155-161.

J. A. Valle, K. Josey, A. F. Prouse, J. Zimmet, and S. W. Waldo, “Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at veterans affairs hospitals,” Heart, vol. 105, no. 20, pp. 1575–1582, 2019.

A. Shafiq, J. Valley, J. S. Jang et al., “Variation in practice regarding pretreatment with dual antiplatelet therapy for patients with non–ST elevation myocardial infarction,” Journal of the American Heart Association, vol. 5, no. 6, Article ID e003576, 2016.

Jonas, M.A., et al., Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation, 1992. 86(5): p. 1664-9.

Klatsky AL. Alcohol and cardiovascular diseases. Expert Rev Cardiovasc Ther. 2009 May;7(5):499-506. doi: 10.1586/erc.09.22. PMID: 19419257.

Rajesh, E. G. (2020). Prescribing Pattern of Anti Platelet Medications of Cardiovascular Disease Patients in Tertiary Care Teaching Hospital. Journal of Medical Science And Clinical Research, 08(05). https://doi.org/10.18535/jmscr/v8i5.24.

Yuksel, Ramazan & Yuksel, Rabia & Sengezer, Tijen & Dane, Senol. (2016). Autonomic Cardiac Activity in Patients with Smoking and Alcohol Addiction by Heart Rate Variability Analysis. Clinical & Investigative Medicine. 39. 147. 10.25011/cim.v39i6.27519.

Day E, Rudd JHF. Alcohol use disorders and the heart. Addiction. 2019 Sep;114(9):1670-1678. doi: 10.1111/add.14703. Epub 2019 Jul 15. PMID: 31309639; PMCID: PMC6771559.

Newton JL. Improving the gastrointestinal tolerability of aspirin in older people. Clin Interv Aging. 2006;1(1):33-9. doi: 10.2147/ciia.2006.1.1.33. PMID: 18047255; PMCID: PMC2682452.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. doi: https://doi.org/10.1038/clpt.1981.154.

Ramalingam K, Rajagopal SS, Kansamy K, Krishnan K. A prospective study on potential drug interactions among hospitalized patients in the cardiology departments in tertiary care hospitals. IJAR. 2018 [cited 2019 Jan 31];(5):65-8. Available from: https://www.worldwidejournals.com/indian-journal-of-applied-research-(IJAR)/fileview/May_2018_1525699051__108.pdf

» https://www.worldwidejournals.com/indian-journal-of-applied-research-(IJAR)/fileview/May_2018_1525699051__108.pdf

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a focused update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use.Circulation.2010;122:2619 –2633.

Kapp PA, Klop AC, Jenkins LS. Drug interactions in primary health care in the George subdistrict, South Africa: A cross-sectional study. S Afr Fam Pract. 2013;55:78–84. [Google Scholar]